Kenvue's Profitability Streak Without Revenue Growth Finally Reaches a Decision Point

Kenvue Inc. reports first-quarter 2026 earnings tomorrow morning before the market opens, with Wall Street watching to see whether the consumer health giant can sustain the momentum from its recent string of earnings beats. The company has exceeded analyst expectations in each of the past four quarters—most recently by a striking 22.73% in Q4 2025—raising the bar for what investors will demand from this release. With the stock trading near its short-term moving averages and options pricing a modest 2.21% expected move, the question is whether Kenvue can deliver another upside surprise or if the streak finally breaks.

Part 1: Earnings Preview

Kenvue is a leading global consumer health company that owns iconic over-the-counter healthcare and personal care brands including Tylenol, Band-Aid, Neutrogena, Listerine, and ZYRTEC. The company operates across three primary segments—Self Care, Skin Health & Beauty, and Essential Health—serving consumers through retail, pharmacy, and e-commerce channels worldwide.

Kenvue is scheduled to report Q1 2026 results on May 7, 2026, before the market opens, with a conference call at 9:30 AM ET. Analysts expect earnings of $0.27 per share, representing 12.50% growth compared to the $0.24 reported in Q1 2025. The company most recently reported $0.27 per share for Q4 2025, beating estimates by 22.73%. Revenue is projected at approximately $3.84 billion for the quarter.

Three key themes define this earnings story:

Pricing Power vs. Volume Dynamics: Investors will scrutinize whether Kenvue can maintain pricing discipline in a competitive consumer health environment while protecting market share. The company's ability to offset cost inflation through price increases without sacrificing volume growth remains critical to margin expansion and will be a focal point of management commentary.

Brand Portfolio Performance: With a stable of household names, the relative strength across Self Care, Skin Health & Beauty, and Essential Health segments will signal whether Kenvue's diversification strategy is working. Analysts are particularly interested in innovation pipeline updates and whether new product launches are gaining traction in key categories.

Operational Efficiency and Margin Trajectory: As an independent company following its 2023 spin-off from Johnson & Johnson, Kenvue's progress on cost structure optimization and advertising efficiency (A&P spending as a percentage of sales) will be closely watched. Free cash flow generation and capital allocation priorities remain top of mind for long-term investors evaluating the company's standalone profile.

Ahead of the release, analyst sentiment remains cautious. The consensus rating sits at 3.15 (Hold), with 12 of 13 analysts maintaining Hold ratings and only one Strong Buy. The average price target of $19.09 implies modest upside from current levels, suggesting Wall Street is taking a wait-and-see approach despite the recent earnings beat streak.

Part 2: Historical Earnings Performance

Kenvue has established a consistent pattern of exceeding analyst expectations, beating estimates in all four of the most recent quarters. The magnitude of these beats has been notable: Q1 2025 delivered a 9.09% surprise ($0.24 actual vs. $0.22 estimate), Q2 2025 came in 3.57% above consensus ($0.29 vs. $0.28), Q3 2025 posted a 3.70% beat ($0.28 vs. $0.27), and Q4 2025 produced the largest upside surprise at 22.73% ($0.27 vs. $0.22).

The trend shows not only consistency but acceleration in the size of beats. While the first three quarters of 2025 saw relatively modest surprises in the 3–9% range, the Q4 result represented a significant step-up that likely reflected both operational execution and conservative analyst positioning. This track record has raised the bar for tomorrow's release—investors now expect Kenvue to clear estimates, and the question has shifted from whether the company will beat to by how much.

The year-over-year comparison for Q1 shows healthy growth expectations, with the $0.27 consensus representing 12.50% improvement over the prior-year quarter's $0.24. If Kenvue delivers another beat of similar magnitude to recent quarters, actual results could land in the $0.28–$0.29 range, which would represent mid-teens percentage growth and further validate the company's post-spin-off momentum.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Kenvue typically reports before the market opens, meaning Day 0 represents the first full trading session where investors react to results, while Day +1 captures follow-through momentum.

Historical price behavior around Kenvue earnings shows significant volatility on the day of the release, with an average absolute Day 0 move of 5.75% and an average intraday range of 5.11%. The direction has been mixed but generally positive in recent quarters—the stock posted strong Day 0 gains of 14.68% (August 2024), 5.24% (May 2024), and 12.32% (November 2025), though it also experienced sharp declines of 4.53% (February 2025) and more modest pullbacks in other periods.

Day +1 follow-through has been more subdued, averaging 1.89% in absolute terms with a 3.08% intraday range. This pattern suggests the bulk of the market's reaction occurs immediately on earnings day, with the next session typically seeing consolidation or modest continuation. The most recent release in February 2026 saw a muted Day 0 decline of 1.55% followed by a 2.55% Day +1 recovery, indicating investors may have initially underreacted before reassessing the strong beat.

For tomorrow's release, history suggests investors should prepare for a potentially volatile Day 0 session with a move in the 4–7% range, followed by more measured action on Day +1. The direction will hinge on whether Kenvue can deliver another meaningful beat and, crucially, what management says about the outlook for the remainder of 2026.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 2.21% through the May 8 weekly expiration, which is notably more conservative than the stock's historical average Day 0 move of 5.75%. This suggests options traders are anticipating a relatively muted reaction compared to past earnings events, possibly reflecting either reduced uncertainty or a belief that recent beats are now priced in. If Kenvue delivers results and guidance that surprise to the upside, the actual move could significantly exceed what options are currently pricing.

Part 3: What Analysts Are Saying

Analyst sentiment on Kenvue remains firmly neutral, with the consensus rating at 3.15 (Hold) and an average price target of $19.09. The rating breakdown shows 1 Strong Buy, 0 Moderate Buys, 12 Holds, 0 Moderate Sells, and 0 Strong Sells among the 13 analysts covering the stock. This distribution reflects a cautious stance from the Street, with the overwhelming majority taking a wait-and-see approach rather than making strong directional calls.

The sentiment trend is classified as unchanged over the past month, indicating analysts have not materially shifted their views despite the company's recent earnings beat streak. The lack of rating upgrades following the strong Q4 2025 surprise suggests the Street may be waiting for evidence that the operational momentum can be sustained over multiple quarters before turning more constructive.

Price targets range from a low of $17.00 to a high of $22.00, with the consensus $19.09 target implying approximately 8.0% upside from the current price of $17.68. This modest upside potential aligns with the Hold-heavy rating distribution and suggests analysts see the stock as fairly valued at current levels. For the consensus view to shift meaningfully, Kenvue would likely need to deliver not just another earnings beat but also raise full-year guidance and demonstrate accelerating organic growth across its brand portfolio.

Part 4: Technical Picture

The Barchart Technical Opinion currently shows a Sell signal at 8%, representing a dramatic improvement from the 56% Sell reading one week ago and the 72% Sell signal one month ago. This rapid shift from deeply oversold conditions to a minimal sell signal suggests the stock has stabilized and may be building a base heading into earnings.

Timeframe Analysis:

• Short-term (50% Sell): Moderate sell signal indicates near-term momentum remains slightly negative, though the reading is neutral enough to suggest the stock is in a transition phase rather than a clear downtrend
• Medium-term (50% Buy): Moderate buy signal reflects improving momentum in the intermediate timeframe, suggesting the recent stabilization may be gaining traction
• Long-term (Hold): Neutral reading indicates the longer-term trend lacks clear direction, with the stock consolidating after its post-spin-off volatility

Trend Characteristics: The combination of Minimum strength and Weakest direction signals a low-conviction environment where the stock is range-bound and lacking a clear catalyst—precisely the setup where an earnings surprise could break the stalemate.

From a moving average perspective, KVUE is trading above its 5-day ($17.43), 10-day ($17.44), 20-day ($17.42), 50-day ($17.64), and 100-day ($17.61) moving averages, but remains below the 200-day moving average at $17.87. This configuration shows short- and intermediate-term support but suggests the stock has yet to reclaim its longer-term uptrend. The cluster of moving averages in the $17.40–$17.65 range creates a technical floor that has held through recent volatility, while the 200-day average at $17.87 represents the key resistance level to watch if earnings spark a rally. The overall technical setup is neutral to slightly supportive—the stock is not oversold or breaking down, but it also lacks the momentum to suggest a major breakout is imminent without a fundamental catalyst. Tomorrow's earnings represent the clearest opportunity for KVUE to either reclaim the 200-day average and shift the technical picture bullish, or fail to hold current support and resume the weakness seen earlier this year.